Skip to main content

Advertisement

SpringerLink
Log in

Current status of stem cell transplantation for multiple myeloma

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Stem cell transplantation for myeloma has become a standard of care for newly diagnosed patients. Current evidence favors tandem transplants for those patients not achieving a complete or very good partial response (<90%) after the first transplant. Transplantation is safe and has been shown to prolong survival even in patients 65 to 70 years of age. Whether the new agents thalidomide, lenalidomide, and bortezomib will have an impact on the survival advantage of stem cell transplantation is unknown.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Gulbrandsen N, Wisloff F, Brinch L, et al.: Healthrelated quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 2001, 18:65–77.

    Article  PubMed  CAS  Google Scholar 

  2. Badros A, Barlogie B, Siegel E, et al.: Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001, 114:600–607.

    Article  PubMed  CAS  Google Scholar 

  3. Badros A, Barlogie B, Siegel E, et al.: Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001, 114:822–829.

    Article  PubMed  CAS  Google Scholar 

  4. Moreau P, Misbahi R, Milpied N, et al.: Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma. Leukemia 2002, 16:1838–1843.

    Article  PubMed  CAS  Google Scholar 

  5. Le Blanc R, Montminy-Metivier S, Belanger R, et al.:Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versusmyeloma effect. Bone Marrow Transplant 2001, 28:841–848.

    Article  Google Scholar 

  6. Imrie K, Esmail R, Meyer RM, et al.: The role of highdose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the Cancer Care Ontario Practice Guidelines Initiative. Ann Intern Med 2002, 136:619–629. An important evidence-based review on single and tandem transplantation versus conventional chemotherapy in myeloma.

    PubMed  Google Scholar 

  7. Attal M, Harousseau JL: Randomized trial experience of the Intergroupe Francophone du Myelome. Semin Hematol 2001, 38:226–230.

    Article  PubMed  CAS  Google Scholar 

  8. Child JA, Morgan GJ, Davies FE, et al.: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875–1883. A landmark article demonstrating survival advantage of stem cell transplantation over conventional chemotherapy.

    Article  PubMed  CAS  Google Scholar 

  9. Vesole DH, Simic A, Lazarus HM: Controversy in multiple myeloma transplants: tandem autotransplants and miniallografts. Bone Marrow Transplant 2001, 28:725–735.

    Article  PubMed  CAS  Google Scholar 

  10. Lenhoff S, Hjorth M, Holmberg E, et al.: Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a populationbased study. Blood 2000, 65:7–11.

    Google Scholar 

  11. Palumbo A, Triolo S, Argentino C, et al.: Dose-intensive melphalan with stem cell support (MEL 100) is superior to standard treatment in elderly myeloma patients. Blood 1999, 94:1248–1253.

    PubMed  CAS  Google Scholar 

  12. Blade J, Sureda A, Ribera JM, et al.: High-dose therapy autotransplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial treatment chemotherapy: results of a prospective randomized trial from the Spanish cooperative group PETHEMA [abstract]. Blood 2001, 98:815a.

    Google Scholar 

  13. Fermand J-P, Ravaud P, Katsahian S, et al.:High-dose therapy (HDT) and autologous blood stem cell (ABSC) transplantation versus conventional treatment in multiple myeloma (MM): results of a randomized trial in 190 patients 55 to 65 years of age [abstract]. Blood 1999,94(Suppl 1):396a.

    Google Scholar 

  14. Schenkein DP, Koc Y, Alcindor T, et al.: Treatment of primary resistant or relapsed multiple myeloma with high-dose chemoradiotherapy, hematopoietic stem cell rescue, and granulocyte-macrophage colonystimulating factor. Biol Blood Marrow Transplant 2000, 6:448–455.

    Article  PubMed  CAS  Google Scholar 

  15. Worel N, Greinix H, Ackermann J, et al.: Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma. Ann Hematol 2001, 80:345–348.

    Article  PubMed  CAS  Google Scholar 

  16. Tricot G, Spencer T, Sawyer J, et al.: Predicting longterm (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002, 116:211–217.

    Article  PubMed  Google Scholar 

  17. Rajkumar SV, Fonseca R, Dispenzieri A, et al.: Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000, 26:979–983.

    Article  PubMed  CAS  Google Scholar 

  18. Alexanian R, Weber D, Giralt S, et al.: Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001, 27:1037–1043.

    Article  PubMed  CAS  Google Scholar 

  19. Morineau N, Tang XW, Moreau P, et al.: Lack of benefit of CD34+ cell selected over nonselected peripheral blood stem cell transplantation in multiple myeloma: results of a single center study. Leukemia 2000, 14:1815–1820.

    Article  PubMed  CAS  Google Scholar 

  20. Barbui AM, Galli M, Dotti G, et al.: Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. Br J Haematol 2002, 116:202–210.

    Article  PubMed  Google Scholar 

  21. Segeren CM, Sonneveld P, van der Holt B, et al.: Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase III study. Blood 2003, 101:2144–2151. A comparison of the efficacy of intensified chemotherapy followed by stem cell transplantation with intensified chemotherapy alone in newly diagnosed myeloma. Intensified chemotherapy followed by myeloablative therapy resulted in a higher complete response and longer time to progression but did not result in better event-free or overall survival.

    Article  PubMed  CAS  Google Scholar 

  22. Cavo M, Tosi P, Zamagni E, et al.: The “Bologna 96” clinical trial of single versus double autotransplant for previously untreated multiple myeloma patients [abstract]. Blood 2002, 100:179a.

    Article  Google Scholar 

  23. Fermand J-P, Marolleau J-P, Alberti C, et al.: In single versus tandem high-dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34 enriched ABSC: preliminary results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM) [abstract]. Blood 2001, 98:815a.

    Google Scholar 

  24. Rajkumar SV, Kyle RA, Gertz MA: Myeloma and the newly diagnosed patient: a focus on treatment and management. Semin Oncol 2002, 29(Suppl 17):5–10.

    Article  PubMed  Google Scholar 

  25. Perea G, Sureda A, Martino R, et al.: Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma. Ann Hematol 2001, 80:592–587.

    Article  PubMed  CAS  Google Scholar 

  26. Morgan AE, Smith WK, Levenson JL: Reversible dementia due to thalidomide therapy for multiple myeloma. N Engl J Med 2003, 348:1821–1822.

    Article  PubMed  Google Scholar 

  27. Yakoub-Agha I, Attal M, Dumontet C, et al.: Thalidomide in patients with advanced multiple myeloma: a study of 83 patients. Report of the Intergroupe Francophone du Myelome (IFM). Hematol J 2002, 3:185–192.

    Article  PubMed  CAS  Google Scholar 

  28. Rajkumar SV, Hayman S, Gertz MA, et al.: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002, 20:4319–4323.

    Article  PubMed  CAS  Google Scholar 

  29. Alexanian R, Weber D, Giralt S, Delasalle K: Consolidation therapy of multiple myeloma with thalidomidedexamethasone after intensive chemotherapy. Ann Oncol 2002, 13:1116–1119.

    Article  PubMed  CAS  Google Scholar 

  30. Rajkumar SV, Gertz MA, Lacy MQ, et al.: Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003, 17:775–779.

    Article  PubMed  CAS  Google Scholar 

  31. Harousseau JL: High-dose therapy in multiple myeloma. Ann Oncol 2002, 13(Suppl 4):49–54.

    PubMed  Google Scholar 

  32. Moreau P, Facon T, Attal M, et al.: Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002, 99:731–735.

    Article  PubMed  CAS  Google Scholar 

  33. Kumar A, Loughran T, Alsina M, et al.: Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol 2003, 4:293–304.

    Article  PubMed  Google Scholar 

  34. Maloney DG, Molina AJ, Sehebi F, et al.: Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003.

  35. Rajkumar SV, Gertz MA, Kyle RA, Greipp PR: Current therapy for multiple myeloma. Mayo Clin Proc 2002, 77:813–822.

    PubMed  CAS  Google Scholar 

  36. Boccadoro M, Palumbo A, Bringhen S, et al.: Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002, 87:846–850.

    PubMed  CAS  Google Scholar 

  37. Kazmi MA, Ahsan G, Schey SA: The effects of prior induction therapy with melphalan on subsequent peripheral blood progenitor cell transplantation for myeloma. Clin Lab Haematol 2001, 23:125–129.

    Article  PubMed  CAS  Google Scholar 

  38. Watts MJ, Ings SJ, Flyn M, et al.: Remobilization of patients who fail to achieve minimal progenitor thresholds at the first attempt is clinically worthwhile. Br J Haematol 2000, 111:287–291.

    Article  PubMed  CAS  Google Scholar 

  39. Morris CL, Siegel E, Barlogie B, et al.: Mobilization of CD34+ cells in elderly patients (greater than or equal to 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003, 120:413–423.

    Article  PubMed  Google Scholar 

  40. Demirer T, Ayli M, Ozcan M, et al.: Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002, 116:468–474.

    Article  PubMed  CAS  Google Scholar 

  41. Desikan KR, Tricot G, Munshi NC, et al.: Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J Haematol 2001, 112:242–247.

    Article  PubMed  CAS  Google Scholar 

  42. Galimberti S, Morabito F, Guerrini F, et al.: Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Br J Haematol 2003, 120:405–412.

    Article  PubMed  Google Scholar 

  43. Sirohi B, Powles R, Mehta J, et al.: The implication of compromised renal function at presentation in myeloma: similar outcome in patients who receive high-dose therapy: a single-center study of 251 previously untreated patients. Med Oncol 2001, 18:39–50.

    Article  PubMed  CAS  Google Scholar 

  44. Shimoni A, Smith TL, Aleman A, et al.: Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant 2001, 27:821–828.

    Article  PubMed  CAS  Google Scholar 

  45. Gertz MA, Lacy MQ, Inwards DJ, et al.: Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant 2000, 26:45–50.

    Article  PubMed  CAS  Google Scholar 

  46. Porrata LF, Gertz MA, Inwards DJ, et al.: Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001, 98:579–585.

    Article  PubMed  CAS  Google Scholar 

  47. Gahrton G, Svensson H, Cavo M, et al.: Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001, 113:209–216.

    Article  PubMed  CAS  Google Scholar 

  48. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al.:Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000, 18:3031–3037.

    PubMed  CAS  Google Scholar 

  49. Kyle RA: Management of patients with multiple myeloma: emphasizing the role of high-dose therapy. Clin Lymphoma 2001, 2:21–28.

    Article  PubMed  CAS  Google Scholar 

  50. Martinelli G, Terragna C, Zamagni E, et al.: Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica 2000, 85:930–934.

    PubMed  CAS  Google Scholar 

  51. Bensinger WI: Allogeneic hematopoietic cell transplantation for multiple myeloma. Biomed Pharmacother 2002, 56:133–138.

    Article  PubMed  CAS  Google Scholar 

  52. Lee CK, Badros A, Barlogie B, et al.: Prognostic factors in allogeneic transplantation for patients with highrisk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003, 31:73–80.

    Article  PubMed  Google Scholar 

  53. Kroger N, Schwerdtfeger R, Kiehl M, et al.: Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete-remission rate in multiple myeloma. Blood 2002, 100:755–760. An important article promoting the use of cytoreduction with autologous transplantation followed by an attempt at immunologic graft versus myeloma with a nonmyeloablative transplantation. This prospective randomized study shows that total body irradiation does not add value to the conditioning of patients with multiple myeloma.

    Article  PubMed  CAS  Google Scholar 

  54. Bellucci R, Alyea EP, Weller E, et al.: Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood 2002, 99:4610–4617.

    Article  PubMed  CAS  Google Scholar 

  55. Kroger N, Kruger W, Renges H, et al.: Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol 2001, 112:421–423.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, 55905, Rochester, MN, USA

    Morie A. Gertz MD

Authors
  1. Morie A. Gertz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martha Q. Lacy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angela Dispenzieri MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Suzanne Hayman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gertz, M.A., Lacy, M.Q., Dispenzieri, A. et al. Current status of stem cell transplantation for multiple myeloma. Curr. Treat. Options in Oncol. 6, 229–240 (2005). https://doi.org/10.1007/s11864-005-0006-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-005-0006-1

Keywords

Search

Navigation